Dr. Reddy's Laboratories · NSE: DRREDDY · BSE: 500124

Q3 FY23 results · Oct–Dec 2022

Dr. Reddy's Laboratories reported revenue from operations of ₹6,789.80 crore (up 27.2% from Q3 FY22) and net profit of ₹1,243.90 crore (up 75.4% from Q3 FY22) for Q3 FY23 (Oct–Dec 2022), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY23	Q3 FY22	YoY	Q2 FY23	QoQ
Revenue from operations	6,789.80	5,338.30	+27.2%	6,331.80	+7.2%
Other income	58.70	55.80	+5.2%	40.80	+43.9%
Total income	6,848.50	5,394.10	+27.0%	6,372.60	+7.5%
Profit before share of associates & JVs and tax	1,631.70	955.70	+70.7%	1,599.60	+2.0%
Share of profit/(loss) of associates & JVs	6.00	18.50		14.00
Net profit for the period	1,243.90	709.30	+75.4%	1,114.20	+11.6%
EPS, basic (₹)	74.91	42.75	+75.2%	67.13	+11.6%
Net margin (%)	18.3	13.3		17.6

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY23	Q3 FY22	YoY	Q2 FY23	QoQ
Revenue from operations	3,897.60	3,479.60	+12.0%	4,880.30	−20.1%
Other income	51.40	63.00	−18.4%	118.00	−56.4%
Total income	3,949.00	3,542.60	+11.5%	4,998.30	−21.0%
Profit before tax	484.90	463.90	+4.5%	1,692.90	−71.4%
Net profit for the period	324.60	341.10	−4.8%	1,116.30	−70.9%
EPS, basic (₹)	19.54	20.55	−4.9%	67.25	−70.9%
Net margin (%)	8.3	9.8		22.9

Consolidated

Filed with BSE: 25 Jan 2023, 17:52 IST
Board meeting: 25 Jan 2023
Period: 01 Oct 2022 to 31 Dec 2022
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 25 Jan 2023, 17:52 IST
Board meeting: 25 Jan 2023
Period: 01 Oct 2022 to 31 Dec 2022
Review status: Unaudited
Source: XBRL filing on BSE